Liven Pharma Limited reported a significant loss of Rs 7.37 million for the period ended September 30, 2026
Filed as: Financial Results for the Quarter Ended September 30-2026
Summary
Liven Pharma Limited reported a significant loss of Rs 7.37 million for the period ended September 30, 2026, with a revenue of Rs 14.29 million. The company's financial performance is alarming due to substantial operating losses and declining cash reserves.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Revenue | PKR 14.29 million | PKR 8.82 million | +62.1% |
| Net Loss After Tax | PKR 7.37 million | PKR 30.16 million | -75.6% |
| Operating Loss | PKR 17.51 million | PKR 31.75 million | -44.9% |
| Cash and Bank Balances | PKR 8.39 million | PKR 18.25 million | -54.0% |
| Loss Per Share | PKR 0.07 | PKR 0.28 | -75.0% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- The company recorded a revenue of Rs 14.29 million, a 62.06% increase from the prior period's Rs 8.82 million.
- Net loss after taxation was Rs 7.37 million, a significant improvement from the prior period's loss of Rs 30.16 million.
- Operating loss stood at Rs 17.51 million, indicating ongoing challenges in managing operational expenses.
Liven Pharma Limited (LIVEN) on Nafa
Last price Rs 39.19 · Pharmaceuticals · You can own LIVEN shares from your phone.
More LIVEN announcements
- NoticeGeneral Meetings / Briefing Sessions
- NoticeNotice of Corporate Briefing Session
- NoticeBOARD MEETING FOR 1st Quarter Financials 2027
- NoticeCertified True Copy of Resolution Passed in Annual General Meeting Held 26th October 2026
- NoticeCorrection Clarification Regarding Annual Report 2026
- NoticeNotice of Annual General Meeting
Source: Liven Pharma Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.